Chinese Investor Group Buys SciClone

Chinese Investor Group Buys SciClone

The Pharmaceutical sector has been relatively slow on the M&A front this year.  U.S. investors seem content to sit on the sidelines and wait for something to happen, such as the rumored takeover of Bristol-Myers Squibb (NYSE: BMY) by Pfizer.  (NYSE: PFE) Only 43 deals have been announced through June 9, down nearly 47% compared with the same time last year. Then the Chinese investors arrived. On June 8th, 2017, SciClone Pharmaceuticals Inc. (NASDAQ: SCLN), a specialty pharmaceutical company that provides therapies for oncology, infectious diseases, and cardiovascular disorders, was purchased in a going-private transaction by a consortium of buyers. The... Read More »